CiTHERA

CiThera is a French biotechnology company dedicated to developing next-generation cell therapies using induced pluripotent stem cells (iPSCs). Based in the Genopole biocluster, the company focuses on regenerative medicine for cardiovascular diseases, specifically targeting heart failure. CiThera's core technology involves a standardized platform for differentiating iPSCs into high-purity cardiomyocytes, enabling the production of "off-the-shelf" therapeutic products. This approach aims to restore cardiac function in patients with damaged heart tissue following myocardial infarction. The company is currently in the pre-clinical stage, advancing its lead programs toward regulatory filings.